104
Views
8
CrossRef citations to date
0
Altmetric
Research Report

Epidemiology and societal costs of gastroesophageal reflux disease and Barrett’s syndrome in Germany, Italy and Spain

, , , , , , & show all
Pages 225-232 | Published online: 09 Jan 2014

References

  • Agreus L, Borgquist L. The cost of gastro-espohageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics20(5), 347–355 (2002).
  • King A, Macdonald C, Örn C. Understanding gastroesophageal reflux disease (GERD): a patient segmentation analysis. Scand. J. Gastroenterol. Suppl.42(Suppl. 244), 21 (2007) (Abstract P6).
  • Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am. J. Med.104(3), 252–258 (1998).
  • Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett’s oesophagus. Aliment Pharmacol. Ther.27(4), 321–326 (2008).
  • Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol.101, 1900–1920 (2006).
  • Dent J, El-Serag HB, Wallander MA, Joohansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut54, 710–717 (2005).
  • Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am. J. Gastroenterol.98(7), 1487–1493 (2003).
  • Wahlqvist P, Reilly M, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol. Ther.24(2), 259–272 (2006).
  • Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J. Gastroenterol.11(45), 7148–7151 (2005).
  • Giolitto G, Bruzzese D, Sarnelli G et al. Prevalence of GERD symptoms in the general population from a rural area in the south Italy. Dig. Liv. Dis.36(Suppl. 2), S259–S260 (2004).
  • Zagari RM, Fuccio L, Wallander MA et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano Monghidoro study. Gut57, 1354–1359 (2008).
  • Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol. Suppl.231, 20–28 (1999).
  • Valle C, Broglia F, Pistorio A, Tinelli C, Perego M. Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Dig. Dis. Sci.44(9), 1848–1852 (1999).
  • Cuomo R, Cammarota S. A hypothetical road map to reduce acid related diseases costs management. Dig. Liver Dis.40(1), 79–80 (2008).
  • Ponce O, Vegazo B, Beltrán J et al. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol. Ther.23, 175–183 (2006).
  • Díaz-Rubio M, Moreno Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol. Ther.19, 95–105 (2004).
  • Jones RH, Hungin AP, Phillips J, Mills JG. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur. J. Gen. Pract.1, 149–154 (1995).
  • Nocon M, Keil T, Willich SN. Prevalence and sociodemographics of reflux symptoms in Germany – results from a national survey. Aliment Pharmacol. Ther.23, 1601–1605 (2006).
  • Labenz J, Nocon M, Lind T et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am. J. Gastroenterol.101, 2457–2462 (2006).
  • Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA. Three year follow-up of patients with gastroesophageal reflux disease. Gut33, 1016–1019 (1992).
  • Ferraris R, Bonelli L, Conio M, Fracchia M, Lapertosa G, Aste H. Incidence of Barrett’s adenocarcinoma in an Italian population: an endoscopic surveillance programme. Eur. J. Gastroenterol. Hepatol.9(9), 881–885 (1997).
  • Alcedo J, Ferrández A, Arenas J et al. Trends in Barrett’s esophagus diagnosis in Southern Europe: implications for surveillance. Dis. Esophagus22, 239–248 (2009).
  • Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease managements – the Genval workshop report. Gut44(Suppl. 2), S1–S16 (1999).
  • Willich SN, Nocon M, Kulig M et al. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett’s mucosa. Aliment Pharmacol. Ther.23, 371–376 (2006).
  • Salvato C, Terrazzani G, Serraglia D, Ragazzi E, Chinellato A. The epidemiology of therapeutic treatment in gastrointestinal disease in general medical practice: analysis of associated healthcare costs. Pharmacoeconomics IRA4(1), 3–14 (2002).
  • Hughes DA, Marchetti M, Colombo G. Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. Expert Rev. Pharmacoeconomics Outcomes Res.5(1), 29–38 (2005).
  • Graf von der Schulenburg JM, Greiner W, Jost F et al. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health11(4), 539–544 (2007).
  • Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J. Gastroenterol.11, 7148–7151 (2005).
  • Willich SN, Nocon M, Kulig M et al. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett’s mucosa. Aliment Pharmacol. Ther.23, 371–376 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.